DHL Group and Cryoport, Inc. a global provider of supply chain solutions for the life sciences sector, are pleased to announce that DHL has acquired 100% of CRYOPDP, a leading specialty courier focused on clinical trials, biopharma, and cell and gene therapies. In this context, the companies also announced a strategic partnership to strengthen their supply chain service offerings for the global life sciences and healthcare sector.
DHL Group already has an established Life Sciences and Healthcare business, contributing over EUR 5 billion in global revenue in 2024. Building on this foundation, the acquisition of CRYOPDP marks a significant step in DHL’s commitment to enhancing its capabilities in specialized pharma logistics and expanding the breadth of its offering in the rapidly growing life science and healthcare sector. CRYOPDP specializes in providing white-glove courier services essential to the sectors it serves. With operations in 15 countries, CRYOPDP handles over 600,000 shipments per year, servicing customers and patients in over 135 countries worldwide.
Going forward, DHL Supply Chain will further build the potential of its Pharma Specialized Network solution by leveraging the specialty courier expertise of newly acquired CRYOPDP and the global air capabilities of DHL Express and DHL Global Forwarding.
